Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: Prognostic significance and the potential role of allogeneic stem-cell transplantation

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2507-2513

  Chen, Yiming ^a   Cortes, Jorge ^a   Estrov, Zeev ^a   Faderl, Stefan ^a   Qiao, Wei ^a   Abruzzo, Lynne ^a   Garcia Manero, Guillermo ^a   Pierce, Sherry ^a   Huang, Xuelin ^a   Kebriaei, Partow ^a   Kadia, Tapan ^a   De Lima, Marcos ^a   Kantarjian, Hagop ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; CYTOGENETICS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RELAPSE FREE SURVIVAL; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959323833     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.2873     Document Type: Article

References (38)

1. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998 (Pubitemid 28452973)
2. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002 (Pubitemid 35429670)
3. Farag SS, Archer KJ, Mrózek K, et al: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108:63-73, 2006 (Pubitemid 43996625)
4. Fenaux P, Preudhomme C, Laï JL, et al: Cytogenetics and their prognostic value in de novo acute myeloid leukemia: A report on 283 cases. Br J Haematol 73:61-67, 1989 (Pubitemid 19237737)
5. Schiffer CA, Lee EJ, Tomiyasu T, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263-270, 1989 (Pubitemid 19040986)
6. Dastugue N, Payen C, Lafage-Pochitaloff M, et al: Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia 9:1491-1498, 1995
7. Freireich EJ, Cork A, Stass SA, et al: Cytogeneticcs for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 6:500-506, 1992
8. Marcucci G, Mrózek K, Rupport AS, et al: Abnormal cytogenetics at date of morphologic complete remission predicts short overall and diseasefree survival, and higher relapse rate in adult acute myeloid leukemia: Results from Cancer and Leukemia Group B study 8461. J Clin Oncol 22:2410-2418, 2004 (Pubitemid 41115398)
9. Grimwade D, Walker H, Oliver F, et al: What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Bone Marrow Transplant 19:1117-1123, 1997 (Pubitemid 27267736)
10. Grimwade D, Vyas P, Freeman S: Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 22:656-663, 2010
11. Freeman SD, Jovanovic JV, Grimwade D: Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 35:388-400, 2008
12. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
13. Patel B, Rai L, Buck G, et al: Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: Final results of the international trial UKALL XII/ECOG2993. Br J Haematol 148:80-89, 2010
14. Spinelli O, Peruta B, Tosi M, et al: Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 92:612-618, 2007 (Pubitemid 350144263)
15. Perea G, Lasa A, Aventín, et al: Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetic [t (8; 21) and inv (16)]. Leukemia 20:87-94, 2006
16. Weisser M, Haferlach C, Hiddemann W, et al: The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia 21:1177-1182, 2007 (Pubitemid 46831805)
17. Papadaki C, Dufour A, Seibl M, et al: Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: Clonal evolution is a limiting factor. Br J Haematol 144:517-523, 2009
18. Bacher U, Badbaran A, Fehse B, et al: Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 37:135-142, 2009
19. Cilloni D, Renneville A, Hermitte F, et al: Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 27:5195-5201, 2009
20. Hämäläinen MM, Kairisto V, Juvonen V, et al: Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol 80:201-207, 2008 (Pubitemid 351253460)
21. Candoni A, Toffoletti E, Gallina R, et al: Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 25:308-316, 2011
22. Candoni A, Tiribelli M, Toffoletti E, et al: Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 82:61-68, 2009
23. Lapillonne H, Renneville A, Auvrignon A, et al: High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24:1507-1515, 2006 (Pubitemid 46638771)
24. Szczepański T: Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 21:622-626, 2007
25. Brüggemann M, Schrauder A, Raff T, et al: Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 24:521-535, 2010
26. Krampera M, Perbellini, O Vincenzi C, et al: Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica 91:1109-1112, 2006 (Pubitemid 44204779)
27. Kang H, Chen IM, Wilson CS, et al: Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115:1394-1405, 2010
28. Buccisano F, Maurillo L, Spagnoli A, et al: Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia. Blood 116:2295-2303, 2010
29. Al-Mawali A, Gillis D, Lewis I, et al: The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 131:16-26, 2009
30. Maurillo L, Buccisano F, Del Principe MI, et al: Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 26:4944-4951, 2008
31. van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al: Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 24:1599-1606, 2010
32. Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 11:543-552, 2010
33. MRD-AML-BFM Study Group, Langebrake C, Creutzig U, et al: Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM Study Group. J Clin Oncol 24:3686-3692, 2006 (Pubitemid 46630545)
34. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al: Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. Br J Haematol 123:243-252, 2003 (Pubitemid 37305058)
35. Al-Mawali A, Gillis D, Hissaria P, et al: Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 129:934-945, 2008
36. Sievers EL, Lange BJ, Alonzo TA, et al: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101:3398-3406, 2003 (Pubitemid 36857920)
37. van Rhenen A, van Dongen GA, Kelder A, et al: The novel AML stem cell association antigen CLL-1 aids in discrimination between normal and leukemia stem cells. Blood 110:2659-2666, 2007 (Pubitemid 47523190)
38. van Rhenen A, Moshaver B, Kelder A, et al: Aberrant marker expression patterns on the CD34+ CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21:1700-1707, 2007 (Pubitemid 47086760)